Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity.
Immunosuppressive agents have proved to be remarkably successful in controlling the course of a growing number of autoimmune diseases. The usual occurrence of relapses when the treatment is stopped and the persisting risk of long term complications linked to over-immunosuppression have prompt the search for new approaches, aiming at more rapid and selective intervention and earlier onset of therapy. New chemicals and monoclonal antibodies presently represent the main clinical orientations, while at the experimental level major efforts are directed towards peptide therapy (autoantigen, T cell receptor) and tolerance induction.
Bach
J F
JF
Immunology Department, Hôpital Necker, Paris, France.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051379:Mice; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus